The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment
Abstract
Multiple studies demonstrate that the brain in Alzheimer's disease (AD) contains extensive oxidative damage. Most of these studies used advanced‐stage AD patients raising the question of whether oxidative damage is a late effect of neurodegeneration or precedes and contributes to the pathogenesis of AD. Here we describe F 2‐isoprostane (F 2‐IsoP) and F 4‐neuroprostane (F 4‐NP) levels in longitudinally followed, well documented autopsied normal control subjects and patients with amnestic mild cognitive impairment (MCI), and late‐stage AD. Gas chromatography/negative ion chemical ionization/mass spectrometry was used to determine F 2‐IsoP and F 4‐NP levels. Significant increases in F 2‐IsoP levels were found in frontal, parietal and occipital lobes in MCI and late AD compared to controls but no significant differences were present between MCI and late AD. A significant increase in F 4‐NPs was present in parietal and occipital lobes in MCI compared to controls and a significant increase was present in these regions and hippocampus in late AD compared to controls. The only difference betwen MCI and late AD was significantly increased F 4‐NP in hippocampus in late AD. Our data indicate that lipid peroxidation is present in the brain of MCI patients and suggest that oxidative damage may play a role in the pathogenesis of AD. Ann Neurol 2005;58:730–735
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864
Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes
Esterbauer, H., Schaur, R. J., & Zollner, H. (1991) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(91)90192-6 · Cited by 6,672
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Current concepts in mild cognitive impairment
Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., Ritchie, K., Rossor, M., Thal, L., & Winblad, B. (2001) · Archives of Neurology · doi:10.1001/archneur.58.12.1985 · Cited by 4,781
Moms, J. C., Heyman, A., Mohs, R. C., Hughes, J. P., van Belle, G., Fillenbaum, G., Mellits, E. D., & Clark, C. (1989) · Neurology · doi:10.1212/wnl.39.9.1159 · Cited by 4,130
Oxidative stress hypothesis in Alzheimer’s disease
Markesbery, W. R. (1997) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(96)00629-6 · Cited by 2,383
Self-citationOxidative Damage Is the Earliest Event in Alzheimer Disease
Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E. K., Jones, P. K., Ghanbari, H., Wataya, T., Shimohama, S., et al. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.8.759 · Cited by 1,885
Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease
(1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00057-2 · Cited by 981
Oxidative stress in Alzheimer’s disease
Smith, M. A., Rottkamp, C. A., Nunomura, A., Raina, A. K., & Perry, G. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00040-5 · Cited by 895
Advanced glycation end products contribute to amyloidosis in Alzheimer disease
Vitek, M. P., Bhattacharya, K., Glendening, J. M., Stopa, E., Vlassara, H., Bucala, R., Manogue, K., & Cerami, A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.4766 · Cited by 806
Oxidative Alterations in Alzheimer's Disease
Markesbery, W. R., & Carney, J. M. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00215.x · Cited by 784
Self-citationRNA Oxidation Is a Prominent Feature of Vulnerable Neurons in Alzheimer’s Disease
Nunomura, A., Perry, G., Pappolla, M. A., Wade, R., Hirai, K., Chiba, S., & Smith, M. A. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-06-01959.1999 · Cited by 722
Markesbery, W. R., & Lovell, M. A. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00009-8 · Cited by 680
Self-citationPraticò, D., Clark, C. M., Liun, F., Lee, V. Y.-M., & Trojanowski, J. Q. (2002) · Archives of Neurology · doi:10.1001/archneur.59.6.972 · Cited by 584
Castegna, A., Aksenov, M., Aksenova, M., Thongboonkerd, V., Klein, J. B., Pierce, W. M., Booze, R., Markesbery, W. R., & Butterfield, D. A. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00914-0 · Cited by 581
Self-citationCastegna, A., Aksenov, M., Thongboonkerd, V., Klein, J. B., Pierce, W. M., Booze, R., Markesbery, W. R., & Butterfield, D. A. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01103.x · Cited by 581
Self-citationPlasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer’s disease
Rinaldi, P., Polidori, M. C., Metastasio, A., Mariani, E., Mattioli, P., Cherubini, A., Catani, M., Cecchetti, R., Senin, U., & Mecocci, P. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00031-9 · Cited by 549
Evidence of increased oxidative damage in subjects with mild cognitive impairment
Keller, J. N., Schmitt, F. A., Scheff, S. W., Ding, Q., Chen, Q., Butterfield, D. A., & Markesbery, W. R. (2005) · Neurology · doi:10.1212/01.wnl.0000156156.13641.ba · Cited by 539
Self-citationProteomic identification of nitrated proteins in Alzheimer's disease brain
Castegna, A., Thongboonkerd, V., Klein, J. B., Lynn, B., Markesbery, W. R., & Butterfield, D. A. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01786.x · Cited by 535
Self-citationIncreased Nuclear DNA Oxidation in the Brain in Alzheimer's Disease
Gabbita, S. P., Lovell, M. A., & Markesbery, W. R. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71052034.x · Cited by 478
Self-citationNeuropathologic Substrate of Mild Cognitive Impairment
Markesbery, W. R., Schmitt, F. A., Kryscio, R. J., Davis, D. G., Smith, C. D., & Wekstein, D. R. (2006) · Archives of Neurology · doi:10.1001/archneur.63.1.38 · Cited by 460
Self-citationIncreased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease
Wang, J., Xiong, S., Xie, C., Markesbery, W. R., & Lovell, M. A. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03053.x · Cited by 451
Self-citationAcrolein is increased in Alzheimer’s disease brain and is toxic to primary hippocampal cultures
Lovell, M. A., Xie, C., & Markesbery, W. R. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00235-9 · Cited by 450
Self-citationFormation of Isoprostane-like Compounds (Neuroprostanes) in Vivo from Docosahexaenoic Acid
Roberts, L. J., Montine, T. J., Markesbery, W. R., Tapper, A. R., Hardy, P., Chemtob, S., Dettbarn, W. D., & Morrow, J. D. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13605 · Cited by 418
Self-citationMorrow, J. D., & Roberts, L. J. (1999) · Methods in Enzymology · doi:10.1016/s0076-6879(99)00106-8 · Cited by 409
Self-citationIncreased F 2 ‐isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo
Pratico, D., Lee, V. M.-Y., Trojanowski, J. Q., Rokach, J., & Fitzgerald, G. A. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.15.1777 · Cited by 405
“Preclinical” AD revisited: Neuropathology of cognitively normal older adults
Schmitt, F. A., Davis, D. G., Wekstein, D. R., Smith, C. D., Ashford, J. W., & Markesbery, W. R. (2000) · Neurology · doi:10.1212/wnl.55.3.370 · Cited by 369
Self-citationMattson, M. P. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(97)01188-0 · Cited by 344 · cited 1×
“5; (6) no dementia; and (7) clinical evaluation that indicated no other cause for memory decline.”
BackgroundAstrocytes, Not Neurons, Produce Docosahexaenoic Acid (22:6ω‐3) and Arachidonic Acid (20:4ω‐6)
Moore, S. A., Yoder, E., Murphy, S., Dutton, G. R., & Spector, A. A. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb08180.x · Cited by 330
Perry, G., Nunomura, A., Hirai, K., Zhu, X., Prez, M., Avila, J., Castellani, R. J., Atwood, C. S., Aliev, G., Sayre, L. M., et al. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)01113-9 · Cited by 297
Lovell, M. A., Gabbita, S. P., & Markesbery, W. R. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0720771.x · Cited by 291
Self-citationOxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients
Migliore, L., Fontana, I., Trippi, F., Colognato, R., Coppedè, F., Tognoni, G., Nucciarone, B., & Siciliano, G. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.07.016 · Cited by 263
Increased CSF F 2 -isoprostane concentration in probable AD
Montine, T. J., Beal, M. F., Cudkowicz, M. E., O’Donnell, H., Margolin, R. A., McFarland, L., Bachrach, A. F., Zackert, W. E., Roberts, L. J., & Morrow, J. D. (1999) · Neurology · doi:10.1212/wnl.52.3.562 · Cited by 251
Self-citationCerebrospinal fluid F2‐isoprostane levels are increased in Alzheimer's disease
Montine, T. J., Markesbery, W. R., Morrow, J. D., & Roberts, L. J. (1998) · Annals of Neurology · doi:10.1002/ana.410440322 · Cited by 239
Self-citationKeller, J. N., & Mattson, M. P. (1998) · Reviews in the Neurosciences · doi:10.1515/revneuro.1998.9.2.105 · Cited by 217
Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders
Cochran, E. J. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.2.182 · Cited by 215
Mild Cognitive Impairment: Aging to Alzheimer’s Disease
(2003) · doi:10.1093/oso/9780195123425.001.0001 · Cited by 201
Castellani, R. J., Harris, P. L. R., Sayre, L. M., Fujii, J., Taniguchi, N., Vitek, M. P., Founds, H., Atwood, C. S., Perry, G., & Smith, M. A. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00570-6 · Cited by 198
F4 ‐ Isoprostanes as Specific Marker of Docosahexaenoic Acid Peroxidation in Alzheimer's Disease
Nourooz‐Zadeh, J., Liu, E. H. C., Yhlen, B., Änggåard, E. E., & Halliwell, B. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0720734.x · Cited by 187
Reich, E. E., Markesbery, W. R., Roberts, L. J., Swift, L. L., Morrow, J. D., & Montine, T. J. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63968-5 · Cited by 183
Self-citationGalocha, B., Hill, A., Barnett, B. C., Dolan, A., Raimondi, A., Cook, R. F., Brunner, J., McGeoch, D. J., & Ploegh, H. L. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.9.1565 · Cited by 170
Peripheral F2‐isoprostanes and F4‐neuroprostanes are not increased in Alzheimer's disease
Montine, T. J., Quinn, J. F., Milatović, D., Silbert, L. C., Dang, T. N. T., Sanchez, S. C., Terry, E. S., Roberts, L. J., Kaye, J. A., & Morrow, J. D. (2002) · Annals of Neurology · doi:10.1002/ana.10272 · Cited by 157
Self-citationMontine, T. J., Markesbery, W. R., Zackert, W. E., Sanchez, S. C., Roberts, L. J., & Morrow, J. D. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65185-1 · Cited by 115
Self-citationSuppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease
Quinn, J. F., Montine, K. S., Moore, M. M., Morrow, J. D., Kaye, J. A., & Montine, T. J. (2004) · Journal of Alzheimer s Disease · doi:10.3233/jad-2004-6110 · Cited by 75
Self-citationMeasuring cognition in advanced Alzheimer’s disease for clinical trials
Schmitt, F. A., Locke, D. E. C., Ashford, J. W., Reisberg, ., Ferris, S. H., Möbius, H. J., & Stöffler, A. (2002) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6139-5_14 · Cited by 44
Neuropathologic Substrate of Mild Cognitive Impairment
Verma, A. M. (2007) · Yearbook of Neurology and Neurosurgery · doi:10.1016/s0513-5117(08)70062-0 · Cited by 29
(2000) · doi:10.1002/1531-8249(200012)48:6
Cited by
Oxidative stress and neurodegeneration: where are we now?
Halliwell, B. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03907.x · Cited by 2,614
A guide to cell death pathways
Yuan, J., & Ofengeim, D. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00689-6 · Cited by 933
Oxidative stress in the progression of Alzheimer disease in the frontal cortex
Ansari, M. A., & Scheff, S. W. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181cb5af4 · Cited by 605
Oxidative stress hypothesis in Alzheimer’s disease: a reappraisal
Praticò, D. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.09.001 · Cited by 606
Butterfield, D. A., Reed, T., Newman, S. F., & Sultana, R. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.05.037 · Cited by 564
Metadata
- Authors
- Markesbery, W. R., Kryscio, R. J., Lovell, M. A., & Morrow, J. D.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2005-10-20
- Volume
- 58
- Issue
- 5
- Pages
- 730-735
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2114139136
- Cited by
- 273
- References
- 50
- FWCI
- 8.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.